Wainwright: Agios mitapivat Receives FDA Priority Review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
H.C. Wainwright analyst Emily Bodnar notes that Agios Pharmaceuticals announced that the FDA accepted its sNDA for mitapivat, in sickle cell disease under the accelerated approval pathway with a Priority Review and a PDUFA goal date of November 1, 2026. The firm views the Priority Review as a positive regulatory signal, implying that the FDA sees mitapivat as a potential meaningful advance for an underserved, serious condition, warranting a compressed review period of six months vs the standard 10 months. This pulls a potential approval forward by about four months, accelerating the path to launch. Wainwright continues to expect a broad SCD label and a steadfast launch leveraging mitapivat's established hematologist prescriber base. The firm has a Buy rating on Agios with a price target of $54 on the shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to fall
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 37.390
Low
25.00
Averages
36.14
High
62.00
Current: 37.390
Low
25.00
Averages
36.14
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agios Advances Accelerated Approval for Mitapivat in Sickle Cell Disease
- Positive FDA Development: Agios's mitapivat receives Priority Review from the FDA, indicating the agency's recognition of the drug's potential despite failing to significantly reduce sickle cell pain crises, reflecting confidence in the submitted data.
- Stock Price Surge: As of 11 a.m., shares of Agios Pharmaceuticals (NASDAQ: AGIO) rose over 14%, demonstrating market optimism regarding the FDA's accelerated approval, which may attract more investor interest.
- Clinical Trial Outcomes: Although the drug did not meet the primary endpoint for reducing sickle cell pain crises, Agios is still pursuing approval based on a Phase 3 trial completed last year, showcasing the company's ongoing commitment to addressing treatment needs.
- Future Prospects: Agios is conducting the REIGNITE Phase 3 Confirmatory Trial to secure full traditional approval, with results expected next year, which will significantly impact the company's long-term growth trajectory.
See More
Agios Secures FDA Priority Review for Sickle Cell Therapy
- FDA Priority Review: The U.S. FDA has granted Agios' supplemental New Drug Application for Mitapivat a Priority Review, with a decision expected by November 1, 2026, which could make Mitapivat the first oral pyruvate kinase activator available, significantly enhancing treatment options for patients.
- Clinical Trial Results: Agios' Phase 2 and Phase 3 trials in patients aged 16 and older with sickle cell disease demonstrated that Mitapivat significantly improved hemoglobin response, although it did not significantly reduce pain crises or improve fatigue, providing positive data to support FDA approval.
- Stock Price Surge: Following the achievement of a key regulatory milestone, Agios' shares jumped over 14% to their highest level in over seven months, reflecting market optimism ahead of its second-quarter earnings, with shares gaining over 56% year-to-date.
- Analyst Optimism: RBC Capital raised its price target for Agios from $28 to $32 while maintaining a 'Sector Perform' rating, citing expectations for a 'seasonally strong' biotech earnings season, which further bolstered investor confidence.
See More
Agios Pharmaceuticals Shares Surge on Positive FDA News
- Positive FDA Review: Agios Pharmaceuticals' key drug mitapivat has received a Priority Review from the FDA, indicating the agency's recognition of the submitted data, with a decision expected by November 1, despite missing the primary endpoint related to sickle cell pain crises.
- Clinical Trial Success: Mitapivat is already approved for pyruvate kinase deficiency and alpha/beta-thalassemia, and the Phase 3 trial for sickle cell disease met its primary endpoint of hemoglobin response, enhancing its market potential and therapeutic profile.
- Strong Market Reaction: As of 11 a.m. today, Agios shares surged over 14% to $43.25, with a market capitalization of $2.2 billion, reflecting investor optimism regarding the FDA's review outcome and potential for future growth.
- Future Outlook: While the current accelerated approval is provisional, Agios must complete the REIGNITE Phase 3 Confirmatory Trial for full approval, with results not expected until next year, prompting investors to monitor subsequent developments for long-term investment viability.
See More
Agios Pharmaceuticals Receives FDA Priority Review for Pyrukynd Expansion
- FDA Priority Review: Agios Pharmaceuticals' Pyrukynd application has received FDA priority review for label expansion in sickle cell disease, marking a strategic advancement in the company's blood disorder portfolio.
- Significant Market Opportunity: The supplemental New Drug Application is supported by data from the RISE UP Phase 2 and Phase 3 trials, with a projected market opportunity exceeding $10 billion by 2030, indicating strong commercial potential.
- Target Action Date: The FDA has set November 1, 2026, as the target action date for this application, with Agios expressing intent to collaborate closely with the FDA to become the first company to offer an oral PK activator for sickle cell disease.
- Product Line Expansion: Agios currently markets Pyrukynd for adults with blood disorders, further solidifying its position in the rare hematology market and addressing unmet patient needs.
See More
Agios Pharmaceuticals Receives FDA Priority Review for Mitapivat
- FDA Priority Review: Agios Pharmaceuticals announced that its supplemental New Drug Application (sNDA) for mitapivat as a treatment for sickle cell disease has received Priority Review from the FDA, indicating positive progress in the company's drug development efforts.
- Accelerated Approval Pathway: The application was submitted under the FDA's accelerated approval pathway, with a target action date set for November 1, 2026, providing the company with an opportunity for expedited market entry that could lead to significant revenue growth.
- Clinical Trial Support: The sNDA submission is supported by data from Phase 2 and Phase 3 RISE UP clinical trials involving patients aged 16 and older with sickle cell disease, demonstrating the drug's potential efficacy and enhancing market confidence in its therapeutic benefits.
- Stock Price Reaction: Following this announcement, Agios shares rose nearly 2% in pre-market trading, reflecting investor optimism about the company's future prospects and potentially attracting more investor interest in its stock.
See More
Small-Cap Stocks Set for Best Performance in 30 Years
- Strong Small-Cap Performance: Small-cap stocks are on track for their best performance in over 30 years, with the Russell 2000 index reaching 3,033.75, up 21% in 2026, indicating robust market momentum and the potential for the best first half since 1991.
- Investment Recommendations: Bank of America and TD Cowen have recommended several small-cap stocks, including Freshpet and Omnicell, suggesting these companies in healthcare technology, retail, and biotech are well-positioned for growth, making them attractive for investors looking to capitalize on market opportunities.
- Freshpet's Growth Potential: With only a 2.7% share of the pet food market, Freshpet is expected to benefit from the 'pet humanization' trend, and TD Cowen has a buy rating with an $80 price target, indicating about 50% upside potential.
- Omnicell's Product Innovation: Omnicell is set to exceed expectations with new pharmacy automation products like Titan XT and OmniSphere, and Bank of America has a buy rating with a $70 price target, suggesting a 77% upside potential.
See More
Agios Advances Accelerated Approval for Mitapivat in Sickle Cell Disease
- Positive FDA Development: Agios's mitapivat receives Priority Review from the FDA, indicating the agency's recognition of the drug's potential despite failing to significantly reduce sickle cell pain crises, reflecting confidence in the submitted data.
- Stock Price Surge: As of 11 a.m., shares of Agios Pharmaceuticals (NASDAQ: AGIO) rose over 14%, demonstrating market optimism regarding the FDA's accelerated approval, which may attract more investor interest.
- Clinical Trial Outcomes: Although the drug did not meet the primary endpoint for reducing sickle cell pain crises, Agios is still pursuing approval based on a Phase 3 trial completed last year, showcasing the company's ongoing commitment to addressing treatment needs.
- Future Prospects: Agios is conducting the REIGNITE Phase 3 Confirmatory Trial to secure full traditional approval, with results expected next year, which will significantly impact the company's long-term growth trajectory.
See More
Agios Secures FDA Priority Review for Sickle Cell Therapy
- FDA Priority Review: The U.S. FDA has granted Agios' supplemental New Drug Application for Mitapivat a Priority Review, with a decision expected by November 1, 2026, which could make Mitapivat the first oral pyruvate kinase activator available, significantly enhancing treatment options for patients.
- Clinical Trial Results: Agios' Phase 2 and Phase 3 trials in patients aged 16 and older with sickle cell disease demonstrated that Mitapivat significantly improved hemoglobin response, although it did not significantly reduce pain crises or improve fatigue, providing positive data to support FDA approval.
- Stock Price Surge: Following the achievement of a key regulatory milestone, Agios' shares jumped over 14% to their highest level in over seven months, reflecting market optimism ahead of its second-quarter earnings, with shares gaining over 56% year-to-date.
- Analyst Optimism: RBC Capital raised its price target for Agios from $28 to $32 while maintaining a 'Sector Perform' rating, citing expectations for a 'seasonally strong' biotech earnings season, which further bolstered investor confidence.
See More
Agios Pharmaceuticals Shares Surge on Positive FDA News
- Positive FDA Review: Agios Pharmaceuticals' key drug mitapivat has received a Priority Review from the FDA, indicating the agency's recognition of the submitted data, with a decision expected by November 1, despite missing the primary endpoint related to sickle cell pain crises.
- Clinical Trial Success: Mitapivat is already approved for pyruvate kinase deficiency and alpha/beta-thalassemia, and the Phase 3 trial for sickle cell disease met its primary endpoint of hemoglobin response, enhancing its market potential and therapeutic profile.
- Strong Market Reaction: As of 11 a.m. today, Agios shares surged over 14% to $43.25, with a market capitalization of $2.2 billion, reflecting investor optimism regarding the FDA's review outcome and potential for future growth.
- Future Outlook: While the current accelerated approval is provisional, Agios must complete the REIGNITE Phase 3 Confirmatory Trial for full approval, with results not expected until next year, prompting investors to monitor subsequent developments for long-term investment viability.
See More
Agios Pharmaceuticals Receives FDA Priority Review for Pyrukynd Expansion
- FDA Priority Review: Agios Pharmaceuticals' Pyrukynd application has received FDA priority review for label expansion in sickle cell disease, marking a strategic advancement in the company's blood disorder portfolio.
- Significant Market Opportunity: The supplemental New Drug Application is supported by data from the RISE UP Phase 2 and Phase 3 trials, with a projected market opportunity exceeding $10 billion by 2030, indicating strong commercial potential.
- Target Action Date: The FDA has set November 1, 2026, as the target action date for this application, with Agios expressing intent to collaborate closely with the FDA to become the first company to offer an oral PK activator for sickle cell disease.
- Product Line Expansion: Agios currently markets Pyrukynd for adults with blood disorders, further solidifying its position in the rare hematology market and addressing unmet patient needs.
See More
Agios Pharmaceuticals Receives FDA Priority Review for Mitapivat
- FDA Priority Review: Agios Pharmaceuticals announced that its supplemental New Drug Application (sNDA) for mitapivat as a treatment for sickle cell disease has received Priority Review from the FDA, indicating positive progress in the company's drug development efforts.
- Accelerated Approval Pathway: The application was submitted under the FDA's accelerated approval pathway, with a target action date set for November 1, 2026, providing the company with an opportunity for expedited market entry that could lead to significant revenue growth.
- Clinical Trial Support: The sNDA submission is supported by data from Phase 2 and Phase 3 RISE UP clinical trials involving patients aged 16 and older with sickle cell disease, demonstrating the drug's potential efficacy and enhancing market confidence in its therapeutic benefits.
- Stock Price Reaction: Following this announcement, Agios shares rose nearly 2% in pre-market trading, reflecting investor optimism about the company's future prospects and potentially attracting more investor interest in its stock.
See More
Small-Cap Stocks Set for Best Performance in 30 Years
- Strong Small-Cap Performance: Small-cap stocks are on track for their best performance in over 30 years, with the Russell 2000 index reaching 3,033.75, up 21% in 2026, indicating robust market momentum and the potential for the best first half since 1991.
- Investment Recommendations: Bank of America and TD Cowen have recommended several small-cap stocks, including Freshpet and Omnicell, suggesting these companies in healthcare technology, retail, and biotech are well-positioned for growth, making them attractive for investors looking to capitalize on market opportunities.
- Freshpet's Growth Potential: With only a 2.7% share of the pet food market, Freshpet is expected to benefit from the 'pet humanization' trend, and TD Cowen has a buy rating with an $80 price target, indicating about 50% upside potential.
- Omnicell's Product Innovation: Omnicell is set to exceed expectations with new pharmacy automation products like Titan XT and OmniSphere, and Bank of America has a buy rating with a $70 price target, suggesting a 77% upside potential.
See More
